# Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

> **NCT03280264** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Parathyroid Carcinoma
- Primary Hyperparathyroidism

## Interventions

- **DRUG:** KHK7580

## Key facts

- **NCT ID:** NCT03280264
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-30
- **Primary completion:** 2019-04-09
- **Final completion:** 2019-04-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03280264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03280264, "Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03280264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*